Drug intelligence / Profile preview

FCR-001

Development stage: Preclinical
Lead developer: Tourmaline Bio
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

FCR-001 is a preclinical-stage monoclonal antibody being developed by FcR Therapeutics for the treatment of various autoimmune diseases. The therapeutic candidate is designed to target Fc gamma receptors (FcγRs) to modulate or block the overactive interplay between autoantibodies and these receptors, which is a primary driver of chronic inflammation and tissue damage in antibody-mediated autoimmune conditions. By intervening in this signaling pathway, FCR-001 aims to restore immune homeostasis and provide a novel approach to managing autoimmune-driven inflammation.

Targets

FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)

Beyond the preview

Go deeper on FCR-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FCR-001.

Explore the full profile